by Rod Raynovich | Dec 30, 2009 | BIOgraph
The Rayno LifeScience Biotech portfolio is up 11-15% YTD (15%+ with rebalancing as recommended). Among the big winners YTD are Regeneron (REGN) up 40%, Targacept (TRGT) up 880% and Inverness (IMA) up 72%. The portfolio included both biotech and diagnostic companies....
by Rod Raynovich | Dec 23, 2009 | BIOgraph
CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted...
by Rod Raynovich | Dec 21, 2009 | BIOgraph
Seasonality, deals and “healthcare reform lite” spur rally On November 18 we suggested some rebalancing in the Rayno Life Science Portfolio anticipating some year-end optimism.Today we got some help from licensing M&A and financing deals....
by Rod Raynovich | Dec 17, 2009 | BIOgraph
Well known biotech executives “face-off” in Licensing Deal gone awry Xenomics'(XNOM.PK) announced today that an ongoing internal preliminary investigation concluded that Sequenom (SQNM) willfully manipulated its Down Syndrome data in its presentations.In...
by Rod Raynovich | Dec 1, 2009 | BIOgraph
Global market growth for vaccines forecasted at 12% ( Edited version published in Genetic Engineering News Dec. 1, 2009) The potential H1N1pandemic has drawn renewed interest in vaccines. Vaccines over the last 100+ years have been one of the most important agents for...
